PROPOFOL Drug Patent Profile
✉ Email this page to a colleague
When do Propofol patents expire, and what generic alternatives are available?
Propofol is a drug marketed by Amneal, Aspiro, Avet Lifesciences, Dr Reddys, Hikma, Hospira, Innopharma, Sagent Pharms Inc, Teva Parenteral, and Watson Labs Inc. and is included in ten NDAs.
The generic ingredient in PROPOFOL is propofol. There are twelve drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the propofol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Propofol
A generic version of PROPOFOL was approved as propofol by SAGENT PHARMS INC on January 4th, 1999.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PROPOFOL?
- What are the global sales for PROPOFOL?
- What is Average Wholesale Price for PROPOFOL?
Summary for PROPOFOL
Recent Clinical Trials for PROPOFOL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Alabama at Birmingham | Phase 1 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | N/A |
| Assiut University | Phase 3 |
Pharmacology for PROPOFOL
| Drug Class | General Anesthetic |
| Physiological Effect | General Anesthesia |
Medical Subject Heading (MeSH) Categories for PROPOFOL
Anatomical Therapeutic Chemical (ATC) Classes for PROPOFOL
US Patents and Regulatory Information for PROPOFOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amneal | PROPOFOL | propofol | INJECTABLE;INJECTION | 217525-001 | Aug 15, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Innopharma | PROPOFOL | propofol | INJECTABLE;INJECTION | 205576-001 | Sep 16, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Dr Reddys | PROPOFOL | propofol | INJECTABLE;INJECTION | 205067-001 | Nov 15, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
